Inoviq LtdASX: IIQ

IIQ signs EXO-OC validation agreement with Sonic Healthcare

· Issued by Inoviq Ltd via ASX

Filed with ASX · · 3 pages · English

Summary by 6ix AI

This partnership is a significant step in INOVIQ's strategy to enter the US market, addressing a critical need for effective ovarian cancer detection. EXO-OC has shown strong early detection performance, which is crucial for improving outcomes in ovarian cancer patients.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

On 6ix: 6ix.com/news/iiq-signs-exo-oc-validation-agreement-with-sonic-healthcare-1

Release

ASX Announcement INOVIQ SIGNS AGREEMENT WITH SONIC HEALTHCARE USA TO VALIDATE OVARIAN CANCER TEST AND EXPLORE POTENTIAL FUTURE US COMMERCIALISATION • Validation and License Option agreement signed with Sonic Healthcare USA to transfer activities necessary to optimise and validate INOVIQ’s...

Inoviq Ltd on 6ix

Story so far

Earlier from Inoviq

Later from Inoviq

All Inoviq news releases